{
    "clinical_study": {
        "@rank": "53934", 
        "arm_group": {
            "arm_group_label": "Hyper-CVAD + MTX/Ara-C + Rituximab", 
            "arm_group_type": "Experimental", 
            "description": "21-day cycles of Hyper-CVAD and high-dose methotrexate/cytarabine are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.\nHyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and filgrastim 5 ug/kg on days 8-21.\nMethotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing\n      so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells\n      and either kill them or deliver cancer-killing substances to them without harming normal\n      cells. Combining rituximab with chemotherapy may kill more cancer cells.\n\n      PURPOSE: Phase II pilot study to study the effectiveness of combining chemotherapy with\n      rituximab in treating patients who have newly diagnosed mantle cell lymphoma."
        }, 
        "brief_title": "S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "21-day cycles of Hyper-CVAD and high-dose methotrexate/Ara-C are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.\nHyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and G-CSF 5 ug/kg on days 8-21.\nMethotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21.", 
                        "title": "Hyper-CVAD + MTX/Ara-C + Rituximab"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "49"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@lower_limit": "35.0", 
                                            "@upper_limit": "69.8", 
                                            "@value": "57.4"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Full Range", 
                            "param": "Median", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "11"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "38"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "1"
                                            }
                                        }, 
                                        "sub_title": "Hispanic or Latino"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "46"
                                            }
                                        }, 
                                        "sub_title": "Not Hispanic or Latino"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "2"
                                            }
                                        }, 
                                        "sub_title": "Unknown or Not Reported"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Ethnicity (NIH/OMB)", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "American Indian or Alaska Native"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "Asian"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "Native Hawaiian or Other Pacific Islander"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "1"
                                            }
                                        }, 
                                        "sub_title": "Black or African American"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "48"
                                            }
                                        }, 
                                        "sub_title": "White"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "More than one race"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "Unknown or Not Reported"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Race (NIH/OMB)", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Progression-Free Survival (PFS) rate at 1 year. PFS measured from date of registration to date of first observation of progressive disease or death due to any cause. Progressive disease is a 50% increase in the sum of products of greatest diameters (SPD) of target measurable lesions over the smallest sum observed if a complete response (confirmed, or unconfirmed) was not previously achieved; appearance of a new lesion/site; unequivocal progression of non-measurable disease; or death due to disease without prior documentation of progression.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "21-day cycles of Hyper-CVAD and high-dose methotrexate/Ara-C are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.\nHyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and G-CSF 5 ug/kg on days 8-21.\nMethotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21.", 
                                "title": "Hyper-CVAD + MTX/Ara-C + Rituximab"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "49"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "77", 
                                                    "@upper_limit": "96", 
                                                    "@value": "90"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Progression-Free Survival (PFS) rate at 1 year. PFS measured from date of registration to date of first observation of progressive disease or death due to any cause. Progressive disease is a 50% increase in the sum of products of greatest diameters (SPD) of target measurable lesions over the smallest sum observed if a complete response (confirmed, or unconfirmed) was not previously achieved; appearance of a new lesion/site; unequivocal progression of non-measurable disease; or death due to disease without prior documentation of progression.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Progression-free Survival", 
                                    "units": "percentage of participants"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "assessed after cycle 4, after completion of treatment, then every 3 months until 1 year after registration", 
                        "title": "Progression-free Survival", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Complete (CR), complete unconfirmed (CRU) and partial responses (PR). CR is complete disappearance of all measurable and non-measurable disease with the exception of nodes; no new lesions; previously enlarged organs must have regressed in size; and if bone marrow positive at baseline, it must be negative. CRU is complete disappearance of all measurable and non-measurable disease; regressed, non-palpable organs; and one or more exceptions not qualifying for CR (see protocol section 10). PR applies to patients with at least one measurable lesion who do not qualify for CR or CRU. PR is a 50% decrease in sum of products of greatest diameters (SPD) for up to six identified dominant lesions identified at baseline; no new lesions; no increase in the size of liver, spleen or other nodes; and splenic and hepatic nodules must have regressed in size by at least 50% in SPD.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "21-day cycles of Hyper-CVAD and high-dose methotrexate/Ara-C are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.\nHyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and G-CSF 5 ug/kg on days 8-21.\nMethotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21.", 
                                "title": "Hyper-CVAD + MTX/Ara-C + Rituximab"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "49"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "42"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Complete (CR), complete unconfirmed (CRU) and partial responses (PR). CR is complete disappearance of all measurable and non-measurable disease with the exception of nodes; no new lesions; previously enlarged organs must have regressed in size; and if bone marrow positive at baseline, it must be negative. CRU is complete disappearance of all measurable and non-measurable disease; regressed, non-palpable organs; and one or more exceptions not qualifying for CR (see protocol section 10). PR applies to patients with at least one measurable lesion who do not qualify for CR or CRU. PR is a 50% decrease in sum of products of greatest diameters (SPD) for up to six identified dominant lesions identified at baseline; no new lesions; no increase in the size of liver, spleen or other nodes; and splenic and hepatic nodules must have regressed in size by at least 50% in SPD.", 
                                    "param": "Number", 
                                    "title": "Response", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "assessed after cycle 4 and after completion of treatment (168 days)", 
                        "title": "Response", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Overall Survival rate at 1 year. Time to death is from date of registration to date of death due to any cause.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "21-day cycles of Hyper-CVAD and high-dose methotrexate/Ara-C are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.\nHyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and G-CSF 5 ug/kg on days 8-21.\nMethotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21.", 
                                "title": "Hyper-CVAD + MTX/Ara-C + Rituximab"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "49"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "79", 
                                                    "@upper_limit": "97", 
                                                    "@value": "92"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Overall Survival rate at 1 year. Time to death is from date of registration to date of death due to any cause.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Overall Survival", 
                                    "units": "percentage of participants"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "assessed after cycle 4, after completion of treatment, then every 3 months for 2 years, then every 6 months thereafter until 5 years", 
                        "title": "Overall Survival", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "21-day cycles of Hyper-CVAD and high-dose methotrexate/Ara-C are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.\nHyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and G-CSF 5 ug/kg on days 8-21.\nMethotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21.", 
                        "title": "Hyper-CVAD + MTX/Ara-C + Rituximab"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "19", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Adverse Event"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Death"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "7", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Not Eligible"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Withdrawal by Subject"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "2", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Physician Decision"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "56", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "49", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Eligible"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "49", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Eligible and Began Protocol Therapy"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "26", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "30", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "name_or_title": "Study Statistician", 
                "organization": "SWOG Statistical Center", 
                "phone": "206-667-4623"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "title": "Hyper-CVAD + MTX/Ara-C + Rituximab"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "48", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "45", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Anemia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "10", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Febrile neutropenia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "12", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "PRBC transfusion"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "8", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Platelet transfusion"
                                        }
                                    ]
                                }, 
                                "title": "Blood and lymphatic system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "5", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "sub_title": "Sinus tachycardia"
                                    }
                                }, 
                                "title": "Cardiac disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Blurred vision"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Dry eye"
                                        }
                                    ]
                                }, 
                                "title": "Eye disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Abdominal pain/cramping"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "23", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Constipation/bowel obstruction"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "17", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Diarrhea without colostomy"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Dyspepsia/heartburn"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Esophagitis/dysphagia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "20", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Nausea"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "26", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Stomatitis/pharyngitis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "15", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Vomiting"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "23", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Edema"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "43", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Fatigue/malaise/lethargy"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "20", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Fever without neutropenia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hemorrhage w/ 3-4 thrombocyt"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Pain-other"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "8", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Rigors/chills"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "5", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "sub_title": "Allergic reaction"
                                    }
                                }, 
                                "title": "Immune system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "15", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Infection w/o 3-4 neutropenia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "15", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Infection with 3-4 neutropenia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Respiratory infect w/ neutrop"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Respiratory infect w/o neutrop"
                                        }
                                    ]
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "8", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Alkaline phosphatase increase"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Bilirubin increase"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Creatinine increase"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "44", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Leukopenia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "31", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Lymphopenia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "45", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Neutropenia/granulocytopenia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "18", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "SGOT (AST) increase"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "10", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "SGPT (ALT) increase"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "43", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Thrombocytopenia"
                                        }
                                    ]
                                }, 
                                "title": "Investigations"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "9", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Anorexia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "22", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hyperglycemia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hyperuricemia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "12", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hypoalbuminemia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "13", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hypocalcemia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hypoglycemia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "15", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hypokalemia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hypomagnesemia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "11", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hyponatremia"
                                        }
                                    ]
                                }, 
                                "title": "Metabolism and nutrition disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Arthralgia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "9", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Bone pain"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Muscle weakness (not neuro)"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "10", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Myalgia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Myalgia/arthralgia, NOS"
                                        }
                                    ]
                                }, 
                                "title": "Musculoskeletal and connective tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Ataxia (incoordination)"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Dizziness/vertigo, NOS"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "17", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Headache"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "26", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Sensory neuropathy"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Taste disturbance"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Anxiety/agitation"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Insomnia"
                                        }
                                    ]
                                }, 
                                "title": "Psychiatric disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "3", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "sub_title": "Urinary frequency/urgency"
                                    }
                                }, 
                                "title": "Renal and urinary disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Allergic rhinitis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Cough"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "8", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Dyspnea"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "8", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Epistaxis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hypoxia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Pneumonitis/infiltrates"
                                        }
                                    ]
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "35", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Alopecia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Dry skin"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Petechiae/purpura"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "16", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Rash/desquamation"
                                        }
                                    ]
                                }, 
                                "title": "Skin and subcutaneous tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "10", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Hypotension"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Phlebitis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "49"
                                            }, 
                                            "sub_title": "Thrombosis/embolism"
                                        }
                                    ]
                                }, 
                                "title": "Vascular disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "CTCAE (2.0)", 
                    "frequency_threshold": "5"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "4", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "sub_title": "Colitis"
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "sub_title": "Infection with 3-4 neutropenia"
                                    }
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "sub_title": "Second primary"
                                    }
                                }, 
                                "title": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "sub_title": "Ataxia (incoordination)"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "CTCAE (2.0)"
                }, 
                "time_frame": "Every week while on protocol treatment (through 8 cycles or 168 days), and 3 months after removal from protocol treatment (at between 8 and 9 months after beginning treatment)."
            }
        }, 
        "completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the 1-year progression-free survival probability in patients with previously\n           untreated mantle cell lymphoma treated with courses of rituximab and cyclophosphamide,\n           doxorubicin, vincristine, and dexamethasone alternating with courses of rituximab and\n           high-dose cytarabine and methotrexate with leucovorin calcium.\n\n        -  Determine the response rate (complete unconfirmed and complete and partial responses)\n           and survival of patients treated with this regimen.\n\n        -  Determine the toxicity of this regimen in these patients.\n\n        -  Correlate chromosomal breakpoints, translocated immunoglobulin regulatory sequences,\n           and cyclins D1, D2, and D3 with response and progression-free survival in patients\n           treated with this regimen.\n\n        -  Correlate gene expression (measured by DNA microarray analysis) with response and\n           progression-free survival in patients treated with this regimen.\n\n      OUTLINE: This is a pilot, multicenter study.\n\n        -  Courses 1, 3, 5, and 7: Patients receive rituximab IV on day 1 (courses 1, 3, and 5\n           only); cyclophosphamide IV over 3 hours twice a day on days 2-4; doxorubicin IV over 24\n           hours on days 5-7; vincristine IV on days 5 and 12; dexamethasone orally or IV four\n           times a day on days 2-5 and 12-15; and filgrastim (G-CSF) subcutaneously (SC) daily\n           beginning on day 8 and continuing until blood counts recover.\n\n        -  Courses 2, 4, 6, and 8: Patients receive rituximab IV on day 1 (courses 2, 4, and 6\n           only); high-dose methotrexate IV over 24 hours on day 2; high-dose cytarabine IV over 2\n           hours twice a day on days 3-4; oral leucovorin calcium 4 times a day on days 3-10; and\n           G-CSF SC daily beginning on day 5 and continuing until blood counts recover.\n\n      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed within 30 days, every 3 months for 2 years, and then every 6 months\n      for 3 years. Patients with disease progression are followed annually for up to 5 years from\n      study entry.\n\n      PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study within 25\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven stage III/IV or bulky stage II mantle cell lymphoma of one of\n             the following histologic subtypes:\n\n               -  Nodular\n\n               -  Diffuse\n\n               -  Mantle zone\n\n               -  Blastic\n\n          -  Newly diagnosed and previously untreated disease\n\n          -  Bidimensionally measurable disease\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 to 69\n\n        Performance status:\n\n          -  Zubrod 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,000/mm^3\n\n          -  Platelet count at least 100,000/mm^3 (50,000/mm^3 if marrow involvement present)\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 mg/dL (5.0 mg/dL if hepatic involvement present)\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n          -  Creatinine clearance greater than 50 mL/min\n\n        Cardiovascular:\n\n          -  Ejection fraction at least 50% by MUGA or 2-D echocardiogram\n\n          -  No significant abnormalities by EKG\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  Willing to receive blood product transfusions\n\n          -  No known sensitivity to E. coli-derived proteins\n\n          -  No known AIDS syndrome or HIV-associated complex\n\n          -  No other malignancy within the past 5 years except adequately treated basal cell or\n             squamous cell skin cancer or carcinoma in situ of the cervix\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior monoclonal antibody therapy\n\n        Chemotherapy:\n\n          -  No prior chemotherapy for lymphoma\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  No prior radiotherapy for lymphoma\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 8, 2002", 
        "firstreceived_results_date": "March 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00041132", 
            "org_study_id": "CDR0000069445", 
            "secondary_id": [
                "U10CA032102", 
                "S0213"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Hyper-CVAD + MTX/Ara-C + Rituximab", 
                "description": "5 ug/kg", 
                "intervention_name": "filgrastim", 
                "intervention_type": "Biological", 
                "other_name": "G-CSF"
            }, 
            {
                "arm_group_label": "Hyper-CVAD + MTX/Ara-C + Rituximab", 
                "description": "375 mg/m^2 on day 1 of cycles 1-6", 
                "intervention_name": "rituximab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Hyper-CVAD + MTX/Ara-C + Rituximab", 
                "description": "300 mg/m^2 on days 2-4 of cycles 1,3,5,7", 
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "cytoxan"
            }, 
            {
                "arm_group_label": "Hyper-CVAD + MTX/Ara-C + Rituximab", 
                "description": "12 g/m^2 over days 3-4 of cycles 2,4,6,8", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug", 
                "other_name": "Ara-C"
            }, 
            {
                "arm_group_label": "Hyper-CVAD + MTX/Ara-C + Rituximab", 
                "description": "40 mg on days 2-5 and 12-15 of cycles 1,3,5,7", 
                "intervention_name": "dexamethasone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Hyper-CVAD + MTX/Ara-C + Rituximab", 
                "description": "16.6 mg/m^2/day for days 5-7 of cycles 1,3,5,7", 
                "intervention_name": "doxorubicin", 
                "intervention_type": "Drug", 
                "other_name": "adriamycin"
            }, 
            {
                "arm_group_label": "Hyper-CVAD + MTX/Ara-C + Rituximab", 
                "description": "170 mg over days 3-5 of cycles 2,4,6,8", 
                "intervention_name": "leucovorin", 
                "intervention_type": "Drug", 
                "other_name": "leucovorin calcium"
            }, 
            {
                "arm_group_label": "Hyper-CVAD + MTX/Ara-C + Rituximab", 
                "description": "1000 mg/m^2 over days 2-3 of cycles 2,4,6,8", 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug", 
                "other_name": "MTX"
            }, 
            {
                "arm_group_label": "Hyper-CVAD + MTX/Ara-C + Rituximab", 
                "description": "1.4 mg/m^2 on days 5 and 12 of cycles 1,3,5,7", 
                "intervention_name": "vincristine", 
                "intervention_type": "Drug", 
                "other_name": "vincristine sulfate"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Cytarabine", 
                "Methotrexate", 
                "Rituximab", 
                "Dexamethasone", 
                "Doxorubicin", 
                "Vincristine", 
                "Lenograstim", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stage III mantle cell lymphoma", 
            "stage IV mantle cell lymphoma", 
            "contiguous stage II mantle cell lymphoma", 
            "noncontiguous stage II mantle cell lymphoma"
        ], 
        "lastchanged_date": "October 3, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/SWOG-S0213"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Trial of Hyper-CVAD and Methotrexate/ARA C Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma", 
        "overall_official": {
            "affiliation": "OHSU Knight Cancer Institute", 
            "last_name": "Elliot M. Epner, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Progression-Free Survival (PFS) rate at 1 year. PFS measured from date of registration to date of first observation of progressive disease or death due to any cause. Progressive disease is a 50% increase in the sum of products of greatest diameters (SPD) of target measurable lesions over the smallest sum observed if a complete response (confirmed, or unconfirmed) was not previously achieved; appearance of a new lesion/site; unequivocal progression of non-measurable disease; or death due to disease without prior documentation of progression.", 
            "measure": "Progression-free Survival", 
            "safety_issue": "No", 
            "time_frame": "assessed after cycle 4, after completion of treatment, then every 3 months until 1 year after registration"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00041132"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Complete (CR), complete unconfirmed (CRU) and partial responses (PR). CR is complete disappearance of all measurable and non-measurable disease with the exception of nodes; no new lesions; previously enlarged organs must have regressed in size; and if bone marrow positive at baseline, it must be negative. CRU is complete disappearance of all measurable and non-measurable disease; regressed, non-palpable organs; and one or more exceptions not qualifying for CR (see protocol section 10). PR applies to patients with at least one measurable lesion who do not qualify for CR or CRU. PR is a 50% decrease in sum of products of greatest diameters (SPD) for up to six identified dominant lesions identified at baseline; no new lesions; no increase in the size of liver, spleen or other nodes; and splenic and hepatic nodules must have regressed in size by at least 50% in SPD.", 
                "measure": "Response", 
                "safety_issue": "No", 
                "time_frame": "assessed after cycle 4 and after completion of treatment (168 days)"
            }, 
            {
                "description": "Overall Survival rate at 1 year. Time to death is from date of registration to date of death due to any cause.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "assessed after cycle 4, after completion of treatment, then every 3 months for 2 years, then every 6 months thereafter until 5 years"
            }
        ], 
        "source": "Southwest Oncology Group", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Southwest Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2002", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }, 
    "geocoordinates": {}
}